A panel of human mAbs against JEV, including JEV-75, was generated from donors immunized with a GIII vaccine strain (JEV-SA14-14-2)
Alternative Names:
NamesJEV
Reactivity Species : Japanese Encephalitis-Virus Expression Host : HEK-293 Endotoxin Level : 1.0 EU/mg as determined by the LAL method Specificity : JEV-75 activity is directed against the E ectodomain, but not to E-DI or E-DIII. Furthermore, this human Mab showed no cross-reactivity to West Nile Virus or Zika Virus E proteins. JEV-75 binds to the E ectodomain but not to DI or DIII. Alanine scanning mutagenesis at sites corresponding to the E ectodomain cause loss-of-binding at S275 in the DI-DII-hinge region, L180 in the DI-LR, N82 in the DII-LR, W217 in the DII-central interface, and DIII residue F308 in the A-strand epitope. Background : Japanese Encephalitis Virus (JEV) is a mosquito-borne, enveloped, positive-stranded RNA virus in the Flavivirus genus endemic to Asia and parts of the western Pacific1. Symptomatic JEV infection is most common in children in areas of endemicity or travellers to those regions. Severe symptoms occur in ~1% of cases, with a case-fatality ratio of 2030%. Survivors often have serious neurologic, cognitive, or psychiatric sequelae. Five JEV genotypes have been identified and existing vaccines are derived from historically predominant GIII strains.
Clonality:
Monoclonal
Clone Designation:
[JEV-75]
Purity:
>=95% monomer by analytical SEC
* VAT and and shipping costs not included. Errors and price changes excepted
